European Medicines Agency (EMA) Pharmacovigilance Meeting. 12th October 2017.

Activity: Internal positions, career professional development, other peer review and other › Other › Research

Description

The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) re-opened its 2014 review into the use of sodium valproate in women of childbearing potential. My input was into a professional working group where a number of specific questions were to be addressed in order to assist the Committee in their decision meeting.
Period2017
Degree of RecognitionInternational

Keywords

  • teratology
  • pharmacovigilance
  • pregnancy
  • epilepsy
  • anti epileptic drugs
  • neuropsychology
  • neurodevelopment

Documents & Links